Results 121 to 130 of about 8,220,454 (420)

Drug resistant HIV [PDF]

BMJ, 2007
HIV has an impressive ability to replicate, mutate, and diversify, so developing drugs or vaccines that can fully contain the virus is a challenge. The only consistently successful way to prevent replication of HIV is to administer a potent combination regimen that contains at least two and preferably three antiretroviral drugs.
Steven G. Deeks, Hiroyu Hatano
openaire   +3 more sources

Evolutionary interplay between viruses and R‐loops

FEBS Letters, EarlyView.
Viruses interact with specialized nucleic acid structures called R‐loops to influence host transcription, epigenetic states, latency, and immune evasion. This Perspective examines the roles of R‐loops in viral replication, integration, and silencing, and how viruses co‐opt or avoid these structures.
Zsolt Karányi, Zita Képes, Zoltán Szabó, Eszter Csoma, Lóránt Székvölgyi   +4 more
wiley   +1 more source

Novel and reported compensatory mutations in rpoABC genes found in drug resistant tuberculosis outbreaks

Frontiers in Microbiology
BackgroundRifampicin (RIF) is a key first-line drug used to treat tuberculosis, a primarily pulmonary disease caused by Mycobacterium tuberculosis. RIF resistance is caused by mutations in rpoB, at the cost of slower growth and reduced transcription ...
Derek Conkle-Gutierrez, Sarah M. Ramirez-Busby, Bria M. Gorman, Afif Elghraoui, Sven Hoffner, Sven Hoffner, Wael Elmaraachli, Faramarz Valafar   +7 more
doaj   +1 more source

Relapse Versus Reinfection of Recurrent Tuberculosis Patients in a National Tuberculosis Specialized Hospital in Beijing, China

Frontiers in Microbiology, 2018
Tuberculosis (TB) recurrence can result from either relapse of an original infection or exogenous reinfection with a new strain of Mycobacterium tuberculosis (MTB).
Zhaojing Zong, Fengmin Huo, Jin Shi, Wei Jing, Yifeng Ma, Qian Liang, Guanglu Jiang, Guangming Dai, Hairong Huang, Yu Pang   +9 more
doaj   +1 more source

Slowing evolution is more effective than enhancing drug development for managing resistance [PDF]

arXiv, 2013
Drug resistance is a serious public health problem that threatens to thwart our ability to treat many infectious diseases. Repeatedly, the introduction of new drugs has been followed by the evolution of resistance. In principle there are two ways to address this problem: (i) enhancing drug development, and (ii) slowing drug resistance.
arxiv  

Standing genetic variation and the evolution of drug resistance in HIV [PDF]

, 2011
Drug resistance remains a major problem for the treatment of HIV. Resistance can occur due to mutations that were present before treatment starts or due to mutations that occur during treatment. The relative importance of these two sources is unknown.
arxiv   +1 more source

Risk factors for drug resistant tuberculosis in Leicestershire - poor adherence to treatment remains an important cause of resistance [PDF]

, 2013
In the light of rising numbers of tuberculosis (TB) cases in the United Kingdom, the problem of anti-tubercular drug resistance remains a significant concern.
Hayward, AC, Monk, PN, Neal, KR, Pritchard, AJ   +3 more
core   +2 more sources

Identification of functional and diverse circulating cancer‐associated fibroblasts in metastatic castration‐naïve prostate cancer patients

Molecular Oncology, EarlyView.
Cancer‐associated fibroblasts (CAFs) promote cancer growth, invasion (metastasis), and drug resistance. Here, we identified functional and diverse circulating CAFs (cCAFs) in patients with metastatic prostate cancer (mPCa). cCAFs were found in higher numbers and were functional and diverse in mPCa patients versus healthy individuals, suggesting their ...
Richell Booijink, Leon W. M. M. Terstappen, Eshwari Dathathri, Khrystany Isebia, Jaco Kraan, John Martens, Ruchi Bansal   +6 more
wiley   +1 more source

Elucidation of critical chemical moieties of metallo-β-lactamase inhibitors and prioritisation of target metallo-β-lactamases

Journal of Enzyme Inhibition and Medicinal Chemistry
The urgent demand for effective countermeasures against metallo-β-lactamases (MBLs) necessitates development of novel metallo-β-lactamase inhibitors (MBLIs).
Jung Hun Lee, Sang-Gyu Kim, Kyung-Min Jang, Kyoungmin Shin, Hyeonku Jin, Dae-Wi Kim, Byeong Chul Jeong, Sang Hee Lee   +7 more
doaj   +1 more source

TP53 Staining in Tissue Samples of Chronic Lymphocytic Lymphoma Cases: An Immunohistochemical Survey of 51 Cases

Turkish Journal of Hematology, 2017
Objective: Chronic lymphocytic leukemia (CLL) is the most common lymphoproliferative disease in adults. The aim of this study is to find out if the extent of proliferation centers or the immunohistochemical expression of p53 is related to disease ...
İbrahim Kulaç, Çetin Demir, Yahya Büyükaşık, Tezer Kutluk, Aysegül Üner   +4 more
doaj   +1 more source